DEA Schedule III Hearing June 29: What Cannabis Rescheduling Could Actually Mean

The Hearing That Could Change Everything

On June 29, 2026, inside a federal hearing room in Arlington, Virginia, the Drug Enforcement Administration will convene what may prove to be the most consequential proceeding in the history of American cannabis policy. The administrative hearing, scheduled to run through at least July 15, will consider whether marijuana should be moved from Schedule I of the Controlled Substances Act — the most restrictive category, reserved for substances deemed to have no accepted medical use and a high potential for abuse — to Schedule III, a classification that acknowledges medical utility and implies a lower abuse potential.

The hearing arrives after years of bureaucratic maneuvering, scientific review, and political pressure that accelerated dramatically following President Trump's December 2025 executive order directing federal agencies to expedite the rescheduling process. That order, which surprised many in the cannabis policy community given the complicated political dynamics around the issue, set in motion the administrative proceedings now approaching their most critical phase.

How We Got Here

The path to the June 29 hearing stretches back decades, but the immediate timeline begins in October 2022 when President Biden directed the Department of Health and Human Services to conduct a scientific review of marijuana's scheduling. HHS completed that review in August 2023, recommending that cannabis be moved to Schedule III based on its assessment of the drug's medical utility, abuse potential, and safety profile.

The DEA, which has final authority over scheduling decisions under the Controlled Substances Act, received the HHS recommendation and initiated its own review process. In May 2024, the DEA published a proposed rule to reschedule marijuana to Schedule III, opening a public comment period that generated more than 43,000 submissions — the vast majority in favor of rescheduling or further liberalization.

Administrative law judge proceedings were then scheduled to hear testimony from expert witnesses, industry stakeholders, medical professionals, and opponents of rescheduling. These proceedings were delayed multiple times due to procedural challenges and the change in presidential administration, but the December 2025 executive order provided the political impetus to finalize the hearing schedule.

What Schedule III Actually Means

The distinction between Schedule I and Schedule III is not merely bureaucratic — it carries profound implications for research, commerce, taxation, banking, and criminal justice. Understanding what rescheduling would and would not change is essential for anyone following this proceeding.

Under Schedule I, marijuana is classified alongside heroin, LSD, and ecstasy as having no currently accepted medical use, a lack of accepted safety for use under medical supervision, and a high potential for abuse. This classification has been the foundation of federal marijuana prohibition since the Controlled Substances Act was enacted in 1970, and it has shaped every aspect of cannabis policy for more than half a century.

Schedule III substances, by contrast, are defined as having a currently accepted medical use, a moderate to low potential for physical and psychological dependence, and a lower abuse potential than Schedule I or II drugs. Current Schedule III substances include testosterone, ketamine, anabolic steroids, and products containing less than 90 milligrams of codeine per dosage unit.

Moving cannabis to Schedule III would immediately eliminate the most punishing federal tax provision facing the cannabis industry. Section 280E of the Internal Revenue Code prohibits businesses trafficking in Schedule I or II controlled substances from deducting normal business expenses. This provision has forced legal cannabis companies to pay effective tax rates of 40 to 70 percent — a crushing burden that has contributed to widespread financial distress across the industry. Schedule III classification would end 280E's applicability, potentially saving the industry billions of dollars annually.

Research would be significantly easier under Schedule III. While Schedule I research is possible, it requires extensive DEA licensing, security protocols, and historically has been limited to cannabis supplied by a single federally authorized growing facility at the University of Mississippi. Schedule III research still requires approvals but faces far fewer bureaucratic obstacles, potentially opening the floodgates for the clinical trials and epidemiological studies that scientists have long sought to conduct.

Banking access would improve substantially. Federal banking regulators have cited Schedule I status as a primary reason for banks' reluctance to serve cannabis businesses. While rescheduling alone would not guarantee full banking access, it would remove the most significant legal barrier and provide regulatory cover for financial institutions willing to serve the industry.

What Rescheduling Would Not Do

It is equally important to understand the limitations of rescheduling. Moving cannabis to Schedule III would not legalize recreational marijuana at the federal level. Schedule III substances are still controlled — they require prescriptions for legal use and DEA registration for legal production and distribution. The state-legal recreational cannabis markets that now exist in 24 states and the District of Columbia would remain technically in conflict with federal law, even under Schedule III.

Rescheduling would not create a federal regulatory framework for commercial cannabis sales. The current patchwork of state-by-state regulation would persist, and the fundamental tension between state legalization and federal control would remain, albeit in a significantly reduced form.

Criminal justice implications would be meaningful but incomplete. Rescheduling would reduce federal penalties for marijuana offenses, as Schedule III violations carry lower sentences than Schedule I violations. However, it would not automatically expunge the records of individuals previously convicted under the harsher Schedule I penalties, nor would it prevent future federal enforcement against unauthorized marijuana activities.

Interstate commerce in cannabis would remain legally complex. While Schedule III status would theoretically open the door for interstate cannabis trade — a development that could transform the industry's economics — the practical implementation would require additional federal legislation or regulatory action that is not guaranteed to follow rescheduling.

The Hearing Process

The June 29 proceeding will be conducted before a DEA administrative law judge in Arlington, Virginia. The format is quasi-judicial — witnesses will testify under oath, evidence will be presented and challenged, and both proponents and opponents of rescheduling will have the opportunity to make their cases.

Expected witnesses include researchers from academic institutions who have studied cannabis's medical applications, representatives from the pharmaceutical industry with interests in cannabinoid-based medications, physicians who prescribe cannabis in medical marijuana states, patients who use cannabis therapeutically, representatives of the cannabis industry, law enforcement officials, and addiction medicine specialists.

The proceedings are expected to last at least two to three weeks, potentially longer depending on the volume of testimony and procedural motions. After the hearing concludes, the administrative law judge will issue a recommendation to the DEA Administrator, who retains final authority over the scheduling decision.

The timeline from hearing conclusion to final rule is uncertain. Administrative rescheduling proceedings have historically taken months to years to reach final resolution, though the executive order's directive to expedite the process may compress that timeline. Most observers expect a final decision sometime in late 2026 or early 2027.

Industry and Market Implications

The cannabis industry is watching the hearing with intense interest, and markets have already begun pricing in the possibility of rescheduling. Cannabis stocks rallied significantly following the December 2025 executive order and have maintained elevated valuations relative to their pre-announcement levels.

The 280E tax relief alone would be transformative. Multi-state operators have estimated that elimination of 280E would improve their operating margins by 20 to 30 percentage points, turning many currently unprofitable operations into viable businesses. For an industry that has struggled with widespread losses and capital constraints, this single change could be the difference between survival and failure for dozens of companies.

Beyond taxation, rescheduling would likely catalyze institutional investment in the cannabis sector. Many investment funds, pension managers, and banking institutions have avoided cannabis exposure specifically because of its Schedule I status. A move to Schedule III would not eliminate all regulatory risk, but it would lower the barrier sufficiently to attract significant new capital.

The pharmaceutical industry's role is a wild card. Several major pharmaceutical companies have cannabinoid medications in development pipelines, and rescheduling would make the FDA approval process for these drugs more straightforward. Some industry observers worry that pharmaceutical involvement could eventually lead to a more restrictive regulatory framework that favors pharmaceutical-grade products over the diverse product ecosystem that has developed in state-legal markets.

The Political Landscape

The political dynamics surrounding rescheduling are unusually complex. Cannabis policy no longer divides neatly along partisan lines. The December 2025 executive order came from a Republican president, reflecting growing support for cannabis reform within the party's libertarian and populist factions. Democratic support for rescheduling (and typically for further liberalization) has been strong for years.

However, opposition remains. Some law enforcement groups, certain medical associations, and socially conservative organizations continue to argue against rescheduling, citing concerns about youth access, impaired driving, addiction potential, and what they characterize as insufficient evidence of medical benefit.

Public opinion has moved decisively in favor of reform. A 2026 Pew Research poll found that 74 percent of Americans support marijuana legalization, with majority support across all age groups, political affiliations, and geographic regions. Support for the more modest step of rescheduling is even higher, exceeding 80 percent in most polls.

What to Watch For

As the June 29 hearing approaches, several factors will shape both the proceedings and their outcome. The quality and breadth of scientific testimony regarding medical utility will be central — Schedule III classification requires accepted medical use, and the strength of the evidence presented on this point will be scrutinized closely.

The DEA's institutional posture matters as well. The agency has historically resisted rescheduling efforts, and while the executive order has forced the issue forward, the agency's cultural and institutional orientation toward drug enforcement could influence how aggressively it challenges pro-rescheduling testimony.

Legal challenges are virtually certain regardless of the outcome. If the DEA moves forward with rescheduling, opponents will likely challenge the decision in federal court. If the DEA declines to reschedule despite the executive order and HHS recommendation, proponents will challenge that decision with equal vigor.

The June 29 hearing is not the end of the rescheduling process — it is, in many ways, the beginning of its most visible and consequential phase. What happens in that Arlington hearing room will reverberate through federal courtrooms, state legislatures, corporate boardrooms, and kitchen tables across the country for years to come.